Aviance Capital Partners LLC Invests $229,000 in ADMA Biologics, Inc. (NASDAQ:ADMA)

Aviance Capital Partners LLC acquired a new position in ADMA Biologics, Inc. (NASDAQ:ADMA) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 11,450 shares of the biotechnology company’s stock, valued at approximately $229,000.

Other large investors also recently bought and sold shares of the company. Bank of Montreal Can purchased a new position in ADMA Biologics in the 2nd quarter worth approximately $17,886,000. D. E. Shaw & Co. Inc. grew its position in shares of ADMA Biologics by 26.8% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock valued at $76,298,000 after acquiring an additional 1,442,799 shares during the period. Principal Financial Group Inc. increased its stake in shares of ADMA Biologics by 785.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock worth $23,872,000 after purchasing an additional 1,059,394 shares in the last quarter. Castleark Management LLC purchased a new stake in ADMA Biologics in the first quarter worth about $5,400,000. Finally, First Turn Management LLC bought a new position in shares of ADMA Biologics in the third quarter worth approximately $13,293,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $20.63 on Wednesday. The stock has a market cap of $4.88 billion, a PE ratio of 71.25 and a beta of 0.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a twelve month low of $3.60 and a twelve month high of $23.64. The stock has a fifty day simple moving average of $18.57 and a 200-day simple moving average of $14.54.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The company had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter in the previous year, the firm earned $0.01 earnings per share. Equities analysts anticipate that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

Insider Activity

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. This represents a 5.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the transaction, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. This represents a 10.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 466,900 shares of company stock valued at $8,224,121. Insiders own 3.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ADMA. HC Wainwright lifted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th. Finally, Raymond James lifted their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research report on Friday, November 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.